Schrödinger, Inc.

DB:43Z Stock Report

Market Cap: €1.4b

Schrödinger Valuation

Is 43Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 43Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 43Z's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 43Z's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 43Z?

Key metric: As 43Z is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 43Z. This is calculated by dividing 43Z's market cap by their current revenue.
What is 43Z's PS Ratio?
PS Ratio7.3x
SalesUS$193.35m
Market CapUS$1.42b

Price to Sales Ratio vs Peers

How does 43Z's PS Ratio compare to its peers?

The above table shows the PS ratio for 43Z vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
NXU Nexus
4.5x9.8%€1.2b
COP CompuGroup Medical SE KGaA
0.9x1.8%€1.1b
M3V MeVis Medical Solutions
2.5xn/a€44.4m
AJ91 DocCheck
0.8xn/a€39.6m
43Z Schrödinger
7.3x18.9%€1.4b

Price-To-Sales vs Peers: 43Z is expensive based on its Price-To-Sales Ratio (7.3x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 43Z's PS Ratio compare vs other companies in the European Healthcare Services Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
43Z 7.3xIndustry Avg. 2.2xNo. of Companies11PS02.44.87.29.612+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 43Z is expensive based on its Price-To-Sales Ratio (7.3x) compared to the European Healthcare Services industry average (2.2x).

Price to Sales Ratio vs Fair Ratio

What is 43Z's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

43Z PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.3x
Fair PS Ratio3.9x

Price-To-Sales vs Fair Ratio: 43Z is expensive based on its Price-To-Sales Ratio (7.3x) compared to the estimated Fair Price-To-Sales Ratio (3.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 43Z forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€18.31
€30.86
+68.6%
21.1%€48.23€24.11n/a11
Dec ’25€20.70
€30.30
+46.4%
21.1%€47.35€23.68n/a11
Nov ’25€16.62
€29.05
+74.8%
22.0%€46.18€23.09n/a11
Oct ’25€16.00
€29.83
+86.5%
20.9%€44.83€22.42n/a11
Sep ’25€19.11
€29.83
+56.1%
20.9%€44.83€22.42n/a11
Aug ’25€21.83
€31.76
+45.5%
22.2%€46.34€23.17n/a11
Jul ’25€17.61
€33.90
+92.5%
19.5%€46.45€23.22n/a10
Jun ’25€20.06
€33.90
+69.0%
19.5%€46.45€23.22n/a10
May ’25€22.92
€35.39
+54.4%
17.2%€46.94€24.41n/a10
Apr ’25€25.25
€34.88
+38.2%
17.2%€46.26€24.06n/a10
Mar ’25€24.46
€34.88
+42.6%
17.2%€46.26€24.06n/a10
Feb ’25€24.64
€38.87
+57.8%
20.3%€55.27€26.71n/a10
Jan ’25€33.34
€40.57
+21.7%
19.3%€55.04€26.60n/a9
Dec ’24€29.71
€45.13
+51.9%
29.8%€74.87€27.14€20.709
Nov ’24€20.36
€50.46
+147.8%
24.8%€75.54€29.27€16.629
Oct ’24€26.89
€51.29
+90.7%
22.8%€72.70€28.17€16.009
Sep ’24€34.15
€51.29
+50.2%
22.8%€72.70€28.17€19.119
Aug ’24€47.20
€52.98
+12.2%
28.6%€77.81€20.81€21.839
Jul ’24n/a
€51.12
0%
33.9%€79.13€21.16€17.619
Jun ’24n/a
€46.98
0%
38.5%€78.03€20.87€20.069
May ’24n/a
€46.49
0%
40.4%€78.02€21.77€22.928
Apr ’24n/a
€47.70
0%
40.0%€79.84€23.21€25.258
Mar ’24n/a
€51.90
0%
41.2%€83.47€23.45€24.469
Feb ’24n/a
€51.00
0%
42.2%€80.03€21.16€24.649
Jan ’24n/a
€52.43
0%
40.8%€80.99€21.66€33.349
Dec ’23n/a
€60.55
0%
32.4%€85.37€36.73€29.718

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 14:35
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Schrödinger, Inc. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gaurav GoparajuBerenberg
Clarence PowellBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research